Sumitomo Pharma (DNPUF) Stock Price, News & Analysis

Company Overview

Sumitomo Pharma Co., Ltd. engages in the manufacture and sale of pharmaceuticals, food ingredients and additives, veterinary medicines, and others in Japan, North America, China, and internationally. The company offers pharmaceutical products, such as therapeutic agents for Parkinson's disease, uterine fibroids, depression, type 2 diabetes, systemic fungal infection, hypertension, pruritus, advanced prostate cancer, overactive bladder, chronic obstructive pulmonary disease, angina pectoris, and arrhythmia. It provides products for atypical antipsychotic, cultured thymus tissue for pediatric congenital athymia, antiepileptic, and carbapenem antibiotic; and Fabry disease drugs. In addition, the company offers food ingredients and additives, such as polysaccharides, as well as seasonings, such as soups or bouillons; and chemical product materials, which include pharmaceutical excipients, personal care products, coatings and industrial materials, and electronic materials. Further, it provides veterinary medicines for companion animals, such as dogs and cats; and livestock comprising cattle, swine, poultry, horses, and aquacultured fish. It has partnerships with Keio University; RIKEN; Kyoto University; and collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company has a strategic alliance with Roivant Sciences Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was incorporated in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.

Key Stats

• Today's Range: $6.53 to $6.53
• 50-Day Range: $4.00 to $6.53
• 52-Week Range: $1.99 to $6.53
• Volume: N/A
• Average Volume: 461 shs
• Market Capitalization: N/A
• P/E Ratio: 0.11
• Dividend Yield: 220.08%
• Price Target: N/A
• Consensus Rating: N/A

Sumitomo Pharma Stock Analysis - MarketRank™

Sumitomo Pharma scored higher than 5% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Sumitomo Pharma.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Sumitomo Pharma is 0.11, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.74.

Price to Earnings Ratio vs. Sector

The P/E ratio of Sumitomo Pharma is 0.11, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.89.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Sumitomo Pharma has a short interest ratio ("days to cover") of 71153, which indicates bearish sentiment.

Change versus previous month

Short interest in Sumitomo Pharma has recently decreased by 3.84%, indicating that investor sentiment is improving.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Sumitomo Pharma pays a meaningful dividend of 1.27%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Sumitomo Pharma does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Sumitomo Pharma is 24.70%. This payout ratio is at a healthy, sustainable level, below 75%.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Sumitomo Pharma has a short interest ratio ("days to cover") of 71153, which indicates bearish sentiment.

Change versus previous month

Short interest in Sumitomo Pharma has recently decreased by 3.84%, indicating that investor sentiment is improving.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Sumitomo Pharma this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Sumitomo Pharma insiders have not sold or bought any company stock.

Percentage Held by Institutions

Only 7.58% of the stock of Sumitomo Pharma is held by institutions.

DNPUF Stock Analysis - Frequently Asked Questions

How have DNPUF shares performed this year?

Sumitomo Pharma's stock was trading at $4.13 at the beginning of the year. Since then, DNPUF shares have increased by 58.1% and is now trading at $6.53.
View the best growth stocks for 2025 here.

How do I buy shares of Sumitomo Pharma?

Shares of DNPUF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 5/28/2025
• Next Earnings (Estimated): 7/29/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:DNPUF
• CIK: N/A
• Web: www.ds-pharma.com
• Phone: 81 6 6203 5321
• Fax: N/A
• Employees: 6,250
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: 0.11
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A